US Patent

US11311515 — Oxymetazoline compositions

Formulation · Assigned to RVL Pharmaceuticals Inc · Expires 2039-12-16 · 14y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions of oxymetazoline and methods for stabilizing oxymetazoline compositions for long-term storage.

USPTO Abstract

The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.

Drugs covered by this patent

oxymetazoline-hydrochloride (OXYMETAZOLINE HYDROCHLORIDE)

Patent Metadata

Patent number: US11311515
Jurisdiction: US
Classification: Formulation
Expires: 2039-12-16
Drug substance claim: No
Drug product claim: Yes
Assignee: RVL Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.